Healthcare & Medical Devices Global On demand · 24-48h

Global Postoperative Nausea and Vomiting Management Market Strategic Research Report

Global Postoperative Nausea and Vomiting Management Market S…
$3,500 USD
Market Research Reports
Strategic Research Report
Global Postoperative Nausea and Vomiting Management Market
$1.41B2025
12.8%CAGR
2032Forecast
Market Research Reports · Global
Market Research Reports Intelligence Series

By Type: Serotonin Antagonists, Steroids, Dopamine Antagonists, Neurokinin NK-1 Receptor Antagonists, Non-pharmacological Treatment

By Application: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies and Drug Stores

Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America

Key Players: Acacia Pharma, Roche, Novartis AG, Ani Pharmaceuticals, Inc, Camurus AB, Sanofi S.A., Helsinn Holding S.A., Eisai Corporation, Merck and Co., GlaxoSmithKline

Region: Global
Formats: PDF, Excel, Word & PowerPoint
Base year: 2025 · forecast to 2032
Length: 88 pages
Market size 2025
$1.41B
Billion USD
Forecast CAGR
12.8%
2025-2032
Forecast 2032
$3.3B
Projected
区域
5
Asia Pacific · Latin America · MEA · Europe · North America

概述

Scope of the Report

The global Postoperative Nausea and Vomiting Management market size is predicted to grow from US$ 1,410 million in 2025 to US$ 3,226 million in 2032; it is expected to grow at a CAGR of 12.8% from 2026 to 2032.

Postoperative nausea and vomiting (PONV) management refers to the various strategies and interventions used to prevent or treat nausea and vomiting in patients after surgery.

The postoperative nausea and vomiting (PONV) management market is driven by the increasing number of surgical procedures and the growing awareness about the adverse effects of PONV on patients" recovery and satisfaction. Anesthesia-induced nausea and vomiting are common complications after surgery, and effective PONV management is crucial to enhance patient outcomes and reduce healthcare costs associated with extended hospital stays and additional treatments. As a result, there is a rising demand for pharmacological and non-pharmacological interventions, such as antiemetic medications, acupressure, and enhanced recovery protocols, to prevent and alleviate PONV. However, the market also faces challenges, including the variability in individual patient responses to antiemetic treatments and the risk of adverse effects associated with certain medications. Additionally, the availability and affordability of effective PONV management options in different healthcare settings can vary, especially in resource-limited regions. Overcoming these challenges through ongoing research and innovation in PONV management approaches, personalized patient care, and education of healthcare professionals will be essential in driving the growth of the postoperative nausea and vomiting management market and improving the post-surgical experience for patients worldwide.

This report presents a comprehensive overview of the global Postoperative Nausea and Vomiting Management market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

  • Serotonin Antagonists
  • Steroids
  • Dopamine Antagonists
  • Neurokinin NK-1 Receptor Antagonists
  • Non-pharmacological Treatment

Segment by Application

  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies and Drug Stores

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Postoperative Nausea and Vomiting Management market:

  • Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
  • Distributors, channel partners and end users in Hospital Pharmacies, Online Pharmacies, Retail Pharmacies and Drug Stores evaluating demand and sourcing options
  • Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
  • Government agencies, industry associations and research institutions tracking industry developments and policy impact

Market snapshot

Global Postoperative Nausea and Vomiting Management Market Strategic Research Report snapshot, 2025–2032

Source: Market Research Reports
Market size CAGR 12.8%
Regional growth momentum
Market share by segment
Key metrics
Base value
$1.41B
2025
Forecast
$3.3B
2032
CAGR
12.8%
2025–2032
区域
5
global
Key companies
Acacia PharmaRocheNovartis AGAni Pharmaceuticals, IncCamurus ABSanofi S.A.Helsinn Holding S.A.Eisai Corporation
© MarketResearchReports.comDisclaimer: The actual data may vary in the final report which undergoes verification check post order confirmation.

Segments covered in this report

By Type
Serotonin AntagonistsSteroidsDopamine AntagonistsNeurokinin NK-1 Receptor AntagonistsNon-pharmacological Treatment
By Application
Hospital PharmaciesOnline PharmaciesRetail Pharmacies and Drug Stores

Table of contents

Click a chapter to expand
01Executive Summary
02Industry Overview & Forecast
  • 2.1.1 Market Definition and Scope
  • 2.1.2 Market Size and Growth Forecast
  • 2.1.3 Volume Analysis
  • 2.1.4 Segment Outlook by Type
  • 2.1.5 Segment Outlook by Application
  • 2.1.6 Regional Outlook
  • 2.1.7 Structural Developments Shaping the Forecast
  • 2.1.8 Forecast Risks and Sensitivities
03Market Segmentation by Type
  • 3.1 Market Segmentation by Type
  • 3.1.1 Market by Type Overview
  • 3.1.2 Serotonin Antagonists
  • 3.1.3 Steroids
  • 3.1.4 Dopamine Antagonists
  • 3.1.5 Neurokinin NK-1 Receptor Antagonists
  • 3.1.6 Non-pharmacological Treatment
  • 3.1.7 Volume Analysis
04Market Segmentation by Application
  • 4.1 Market Segmentation by Application
  • 4.1.1 Market by Application Overview
  • 4.1.2 Hospital Pharmacies
  • 4.1.3 Online Pharmacies
  • 4.1.4 Retail Pharmacies and Drug Stores
  • 4.1.5 Volume Analysis
05Regional Market Forecast
  • Asia Pacific
  • North America
  • Europe
  • Middle East & Africa
  • Latin America
06Country-Level Market Forecast
  • 6.1 Asia Pacific
  • 6.1.1 China
  • 6.1.2 Japan
  • 6.1.3 Korea
  • 6.1.4 Southeast Asia
  • 6.1.5 India
  • 6.1.6 Australia
  • 6.1.7 Rest of Asia Pacific
  • 6.2 North America
  • 6.2.1 United States
  • 6.2.2 Canada
  • 6.2.3 Mexico
  • 6.2.4 Rest of North America
  • 6.3 Europe
  • 6.3.1 Germany
  • 6.3.2 France
  • 6.3.3 UK
  • 6.3.4 Italy
  • 6.3.5 Russia
  • 6.3.6 Rest of Europe
  • 6.4 Middle East & Africa
  • 6.4.1 Egypt
  • 6.4.2 South Africa
  • 6.4.3 Israel
  • 6.4.4 Turkey
  • 6.4.5 GCC Countries
  • 6.4.6 Rest of Middle East & Africa
  • 6.5 Latin America
  • 6.5.1 Brazil
  • 6.5.2 Rest of Latin America
07Growth Drivers & Inhibitors
  • 7.1 Growth Drivers & Inhibitors
  • 7.1.1 Section Overview
  • 7.1.2 Growth Drivers
  • 7.1.3 Growth Inhibitors
  • 7.1.4 Driver and Inhibitor Impact Assessment
  • 7.1.5 Analyst Perspective
08Key Company Profiles
  • 8.1 Acacia Pharma
  • 8.1.1 Company Overview
  • 8.1.2 Key Products & Segments
  • 8.1.3 Financial Performance (2023–2025)
  • 8.1.4 Business Strategy
  • 8.1.5 SWOT Analysis
  • 8.1.6 Strategic Implications (2026–2032)
  • 8.2 Roche
  • 8.2.1 Company Overview
  • 8.2.2 Key Products & Segments
  • 8.2.3 Financial Performance (2023–2025)
  • 8.2.4 Business Strategy
  • 8.2.5 SWOT Analysis
  • 8.2.6 Strategic Implications (2026–2032)
  • 8.3 Novartis AG
  • 8.3.1 Company Overview
  • 8.3.2 Key Products & Segments
  • 8.3.3 Financial Performance (2023–2025)
  • 8.3.4 Business Strategy
  • 8.3.5 SWOT Analysis
  • 8.3.6 Strategic Implications (2026–2032)
  • 8.4 Ani Pharmaceuticals, Inc
  • 8.4.1 Company Overview
  • 8.4.2 Key Products & Segments
  • 8.4.3 Financial Performance (2023–2025)
  • 8.4.4 Business Strategy
  • 8.4.5 SWOT Analysis
  • 8.4.6 Strategic Implications (2026–2032)
  • 8.5 Camurus AB
  • 8.5.1 Company Overview
  • 8.5.2 Key Products & Segments
  • 8.5.3 Financial Performance (2023–2025)
  • 8.5.4 Business Strategy
  • 8.5.5 SWOT Analysis
  • 8.5.6 Strategic Implications (2026–2032)
  • 8.6 Sanofi S.A.
  • 8.6.1 Company Overview
  • 8.6.2 Key Products & Segments
  • 8.6.3 Financial Performance (2023–2025)
  • 8.6.4 Business Strategy
  • 8.6.5 SWOT Analysis
  • 8.6.6 Strategic Implications (2026–2032)
  • 8.7 Helsinn Holding S.A.
  • 8.7.1 Company Overview
  • 8.7.2 Key Products & Segments
  • 8.7.3 Financial Performance (2023–2025)
  • 8.7.4 Business Strategy
  • 8.7.5 SWOT Analysis
  • 8.7.6 Strategic Implications (2026–2032)
  • 8.8 Eisai Corporation
  • 8.8.1 Company Overview
  • 8.8.2 Key Products & Segments
  • 8.8.3 Financial Performance (2023–2025)
  • 8.8.4 Business Strategy
  • 8.8.5 SWOT Analysis
  • 8.8.6 Strategic Implications (2026–2032)
  • 8.9 Merck and Co.
  • 8.9.1 Company Overview
  • 8.9.2 Key Products & Segments
  • 8.9.3 Financial Performance (2023–2025)
  • 8.9.4 Business Strategy
  • 8.9.5 SWOT Analysis
  • 8.9.6 Strategic Implications (2026–2032)
  • 8.10 GlaxoSmithKline
  • 8.10.1 Company Overview
  • 8.10.2 Key Products & Segments
  • 8.10.3 Financial Performance (2023–2025)
  • 8.10.4 Business Strategy
  • 8.10.5 SWOT Analysis
  • 8.10.6 Strategic Implications (2026–2032)
09Competitive Landscape
  • 9.1 Competitive Landscape Overview
  • 9.2 Competitive Intensity Assessment
  • 9.3 Key Player Strategies & Positioning
  • 9.4 Competitive Dynamics & Strategic Outlook
  • 9.4.1 Emerging Competitive Threats
  • 9.4.2 Consolidation vs. Fragmentation Outlook
  • 9.4.3 Competitive Response Matrix
  • 9.4.4 Strategic Recommendations, 2026–2032
10Porter's Five Forces Analysis
  • 10.1 Threat of New Entrants
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Threat of Substitutes
  • 10.5 Competitive Rivalry
11PESTLE Analysis
  • 11.1 Political
  • 11.2 Economic
  • 11.3 Social and Demographic
  • 11.4 Technological
  • 11.5 Legal and Regulatory
  • 11.6 Environmental
  • 11.7 Strategic Implications of the PESTLE Assessment
12SWOT Analysis
13Future Trends & Outlook
  • 13.1 Future Trends & Outlook
  • 13.1.1 Trend Summary and Commercial Maturity Assessment
  • 13.1.2 Technology and Innovation Trends
  • 13.1.3 Long-Term Market Outlook
  • 13.1.4 Investment & M&A Activity Outlook
  • 13.1.5 Overall Outlook Assessment

Frequently asked questions

How big is the global Postoperative Nausea and Vomiting Management market?
The global Postoperative Nausea and Vomiting Management market is estimated at US$ 1.41 billion in 2025 (base year) and is projected to reach US$ 3.23 billion by 2032.
How fast is the Postoperative Nausea and Vomiting Management market expected to grow?
The market is expected to grow at a CAGR of 12.8% from 2026 to 2032, expanding from US$ 1.41 billion in 2025 to US$ 3.23 billion in 2032, roughly 2.3 times its base-year value.
What does the Postoperative Nausea and Vomiting Management market cover?
Postoperative nausea and vomiting (PONV) management refers to the various strategies and interventions used to prevent or treat nausea and vomiting in patients after surgery.
What are the main segments of the Postoperative Nausea and Vomiting Management market by type?
By type, the market is segmented into Serotonin Antagonists, Steroids, Dopamine Antagonists, Neurokinin NK-1 Receptor Antagonists and Non-pharmacological Treatment.
Which applications drive demand in the Postoperative Nausea and Vomiting Management market?
Key applications covered include Hospital Pharmacies, Online Pharmacies and Retail Pharmacies and Drug Stores.
Who are the key players in the Postoperative Nausea and Vomiting Management market?
Key players profiled include Acacia Pharma, Roche, Novartis AG, Ani Pharmaceuticals, Camurus AB, Sanofi S.A., Helsinn Holding S.A. and Eisai Corporation, among 10 companies covered in total.
Which regions and countries are covered for Postoperative Nausea and Vomiting Management?
The market is analysed across Asia Pacific, North America, Europe, Middle East & Africa and Latin America, with 20 country-level markets including China, Japan, United States, Canada, Germany, France, Egypt and South Africa.
What is driving growth in the Postoperative Nausea and Vomiting Management market?
The postoperative nausea and vomiting (PONV) management market is driven by the increasing number of surgical procedures and the growing awareness about the adverse effects of PONV on patients" recovery and satisfaction.
What challenges does the Postoperative Nausea and Vomiting Management market face?
However, the market also faces challenges, including the variability in individual patient responses to antiemetic treatments and the risk of adverse effects associated with certain medications.
Who should buy the Postoperative Nausea and Vomiting Management market report?
The report is intended for manufacturers and solution providers, distributors and end users in Hospital Pharmacies, Online Pharmacies and Retail Pharmacies and Drug Stores, investors and consultants, and government or industry bodies who need market size, segmentation, competitive and regional data for the Postoperative Nausea and Vomiting Management market.
What license options are available for this report?
The report is available as a Single User License (US$ 3,500, one named user), a Site License (US$ 5,250, up to 10 users) and a Global / Corporate License (US$ 7,000, unlimited users), all delivered in PDF format.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

01
Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

02
Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

03
Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

04
Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

05
Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

06
Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.

All data sources are cited within the report. View our full research methodology →
Select a license
from US$3,500.00
Report License Type
Optional add-ons
On demand · delivered within 24-48 hours
Secure checkout · SSL encrypted
License terms included
Post-purchase analyst support
Custom research

Need a customized version?

Get country-, segment- or company-specific intelligence tailored to your exact requirements.

Request custom research →
Talk to a research advisor USA: +1-302-703-9904 India: +91-8762746600
Trusted by

Leading Brands in This Industry

Logos are trademarks of their respective owners and indicate a verified past business relationship, not a current partnership or endorsement.